Viatris weighs sale of European consumer health business — report
Following in the footsteps of GSK and J&J, Viatris is reportedly weighing plans to ditch its consumer health assets.
Viatris is considering a deal for its European consumer health programs that could reap more than $2.9 billion, unnamed sources told Bloomberg. While Viatris hasn’t responded to a request for comment, CEO Michael Goettler has previously made clear that he’s on a mission to trim back the company’s “non-core assets.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.